Improvements in safety assessment and greater mechanistic understanding of common adverse events could produce fewer safety-related market withdrawals in the future, recent comments by two leading FDA authorities suggest.
“Some of the major causes of drugs going off the market, I think, are largely gone” because of systematic, prospective...